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Plexiform Neurofibroma Associated with NF1
Stephen M. Purcell, DO and Tatyana Groysman, DO, Lehigh Valley Health Network, Allentown, Pennsylvania
Patient: D.G., a 55 year-old
Caucasian male.
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Figure 1: Overhanging from the posterior
neck is a tender mass with overgrowth of
epidermal and subcutaneous tissues. Also
multiple flesh-toned, pink and tan polypoid, soft, rubbery nodules varying in size
scattered throughout back.
Figure 2: Side view of the overhanging
bag-like mass.
Figure 3: Another diffuse, thick and irregular tumor is noted on the right shoulder.

History of P
 resent Illness: The patient presented to the derma-

tology clinic complaining of a mass extending from the back of his neck. Associated symptoms included headaches, pain upon lying down and sleeping, as well
as inability to keep proper hygiene of the area involved. The physical disfigurement
significantly affected the patient’s quality of life. He reported a prior surgical
excision at the site in childhood. Overtime the lesion recurred, enlarging in size
gradually in a span of 15-20 years. Multiple other neurofibromas were excised in
the past, particularly one on his left flank and his right shoulder. Unfortunately the
patient died of cardio-pulmonary causes in late February.
Medical History/Surgical History: NF1, left Horner syndrome,
COPD, sleep apnea, GERD, DM II, adenocarcinoma of the colon, C2-C4 laminectomy with fusion using left ilial bone graft as a child, left inguinal herniorrhaphy,
multiple neurofibromas excised as per patient
Family History: NF1 in his father, brother, sister, aunts and uncles. He
has 2 sisters who are not affected. Work up of his two daughters is in progress.
Medications: Gabapentin, mirtazapine, diclofenac, glucophage, omeprazole, montelukast, ipratropium inhaler, salbutamol inhaler, fluticasone propionate
nasal spray
Previous Treatments: Surgical excisions
Physical Examination: Overhanging from the posterior neck a
tender mass with overgrowth of epidermal and subcutaneous tissue associated
with a wrinkled and “peau d’orange” texture. Another diffuse, thick and irregular
tumor is noted on the right shoulder. Multiple flesh-toned, pink and tan polypoid,
soft, rubbery nodules varying in size scattered throughout the trunk and
extremities. Axillary freckling is present.
Studies: Cervical spine MRI, April 2007:
“7.1x2.3x2.8 cm plexiform neurofibroma arising from
the roots and trunks of the right brachial plexus. Right
C2-C3 through C6-C7 neural foraminal neurofibromas
or schwannomas, the largest of which measures
approximately 1.7 cm at C
 4-C5. Small nerve sheath
tumor of the adipose tissues inferior to the left occipital
bone”. Cervical spine MRI in September 2010 showed Axial T2-weighted cervical
“no interval change involving the right brachial plexus spine MRI (4-24-2007)
neurofibroma but did reveal enlargement of exiting
nerve roots bilaterally, more on the right side without a discrete mass.”
Reason for Presentation: Interest
Discussion: Plexiform neurofibroma (PN) is a benign peripheral nerve
sheath tumor, considered to be pathognomonic of neurofibromatosis type 1 (NF1).
It is seen in about 15-30% of individuals with NF1, typically presenting at birth or
becoming physically apparent within the first 2-5 years of life. PN c linically features a diffuse large, bag-like mass, often with overlying hyperpigmentation or

hypertrichosis. The tumors can be severely disfiguring and locally invasive, most
commonly involving the trigeminal or upper cervical nerves.

Histopathologically, PNs are similar to discrete neurofibromas: a myxomatous,
hypocellular background with spindle cells, mast cells, fibroblasts and vascular
components arranged in closely packed multiple fascicles. The tumor is intraneural and each part of the plexus is confined by a thickened perineurium.
The natural progression of PN is poorly understood. Certain lesions remain
quiescent for a long time, whereas others may grow aggressively, especially
during childhood and adolescence. Rarely, rapid growth or pain can be suggestive
of m
 alignant transformation. With a lifetime risk of 8-13%, m
 alignant peripheral
nerve sheath tumors (MPNSTs) are not uncommon in NF1 and are one of the
leading causes of premature death. They carry a poor prognosis with a 5-year
survival of only 21-41%.
There is increasing evidence that mutations in genes other than the NF1 gene
contribute to the development of malignancies. Studies have shown that inac
tivation of the p53 tumor suppressor gene, upregulation of the CD44 adhesion
molecule and decreased or lost PTEN expression accompanies MPNST formation.
The management of patients with PN is not well defined and is aimed mostly at
controlling symptoms. Surgical approach is difficult, as it produces poor results
with a high rate of re-growth and potential risk for long-term neurologic sequelae.
Routine MRI scans may be of value in monitoring patients with rapidly growing
tumors.
A novel therapeutic option has emerged as a result of recent research in PN
pathogenesis. A mouse model study concluded that tumor formation is driven
by NF1 heterozygosity in marrow, particularly the mast cells expressing highfunctioning c-kit receptors. Genetic inhibition of c-kit protects against tumorigenic
potential, further confirming these findings. As such, imatinib mesylate (Gleevec),
a potent inhibitor of c-kit receptor tyrosine kinase, successfully reduced existing
PN volume in a mouse model. A case report of a critically ill three-year-old girl
with a PN compressing her airway had a 75% volume reduction of her tumor with
imatinib administration. Imatinib for PN management is now a phase II c linical
trial in its final stages.
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